Education
About Us
Working with TipRanks
Follow Us
Lipocine (LPCN)
NASDAQ:LPCN
LPCN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.91 - $11.79
Previous CloseN/A
Volume16.76K
Average Volume (3M)14.15K
Market Cap
$18.57M
Enterprise Value$4.19M
Total Cash (Recent Filing)$8.08M
Total Debt (Recent Filing)$10.26M
Price to Earnings (P/E)680.4
Beta0.89
Next Earnings
May 08, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding5,350,356
10 Day Avg. Volume12,719
30 Day Avg. Volume14,150
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.69
Price to Cash Flow (P/CF)2.80
P/FCF Ratio2.80
Enterprise Value/Market Cap0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.37
Enterprise Value/Ebitda-0.85
Forecast
1Y Price Target
$6.75Price Target Upside94.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Ownership Overview
15.89%
Insiders
5.22% Mutual Funds
<0.01% Other Institutional Investors
74.59% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
LPCN FAQ
What was Lipocine’s price range in the past 12 months?
Lipocine lowest stock price was $2.91 and its highest was $11.79 in the past 12 months.
What is Lipocine’s market cap?
Lipocine’s market cap is $18.57M.
When is Lipocine’s upcoming earnings report date?
Lipocine’s upcoming earnings report date is May 08, 2025 which is in 41 days.
How were Lipocine’s earnings last quarter?
Lipocine released its earnings results on Mar 13, 2025. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of -$0.4 by $0.73.
Is Lipocine overvalued?
According to Wall Street analysts Lipocine’s price is currently Undervalued.
Does Lipocine pay dividends?
Lipocine does not currently pay dividends.
What is Lipocine’s EPS estimate?
Lipocine’s EPS estimate is -0.35.
How many shares outstanding does Lipocine have?
Lipocine has 5,350,356 shares outstanding.
What happened to Lipocine’s price movement after its last earnings report?
Lipocine reported an EPS of $0.33 in its last earnings report, beating expectations of -$0.4. Following the earnings report the stock price went up 2.804%.
Which hedge fund is a major shareholder of Lipocine?
Currently, no hedge funds are holding shares in LPCN
---
Company Description
Lipocine
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
---
LPCN Stock 12 Month Forecast
Average Price Target
$6.75
▲(94.52% Upside)
Technical Analysis
Neurocrine
―
TherapeuticsMD
―
ANI Pharmaceuticals
―
RedHill Biopharma
―
Viking Therapeutics
―
Best Analysts Covering LPCN
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-14.70%
reiterated a buy rating 9 days ago
Copying Scott Henry's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -14.70% per trade.
---